TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis C$15.32 0.00 (0.00%) As of 07/3/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesBuy This Stock About Fennec Pharmaceuticals Stock (TSE:FRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$15.32▼C$15.3250-Day RangeC$8.45▼C$15.4252-Week RangeC$7.59▼C$15.48VolumeN/AAverage Volume1,326 shsMarket CapitalizationC$532.17 millionP/E RatioN/ADividend Yield2.02%Price TargetN/AConsensus RatingStrong Buy Company Overview Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Read More Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FRX Stock News HeadlinesFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 22, 2026 | financialpost.comFFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 15, 2026 | financialpost.comFThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.July 5 at 1:00 AM | Investors Alley (Ad)Fennec Shareholders Approve Governance, Compensation and Equity PlansJune 10, 2026 | tipranks.comFennec Announces Results of Annual MeetingJune 10, 2026 | financialpost.comFFennec Announces Results of Annual MeetingJune 10, 2026 | markets.businessinsider.comFennec Announces Results of Annual MeetingJune 10, 2026 | globenewswire.comFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comSee More Headlines FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed this year? Fennec Pharmaceuticals' stock was trading at C$10.60 on January 1st, 2026. Since then, FRX shares have increased by 44.5% and is now trading at C$15.32. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc. (TSE:FRX) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 58.09% and a negative net margin of 17.22%. How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray Brands (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Adherex Technologies (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS). Company Calendar Last Earnings11/07/2024Today7/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:FRX CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.29) Trailing P/E RatioN/A Forward P/E Ratio25.37 P/E GrowthN/ANet Income-C$800.44 thousand Net Margins-17.22% Pretax MarginN/A Return on Equity-58.09% Return on Assets8.88% Debt Debt-to-Equity RatioN/A Current Ratio6.98 Quick Ratio10.17 Sales & Book Value Annual SalesC$51.00 million Price / Sales10.43 Cash FlowC$1.31 per share Price / Cash Flow11.66 Book ValueC$1.09 per share Price / Book14.00Miscellaneous Outstanding Shares34,737,000Free FloatN/AMarket CapC$532.17 million OptionableNot Optionable Beta3.52 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (TSE:FRX) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
